SanaCurrents applies data points to assess how likely a company will be able to advance a drug or device, helping us to determine our decision to potentially buy the stock, which we disclose to members.
SanaCurrents Leaves Your BioTech Guesswork Behind
3 hand selected biotech ideas per month with positive outcome Probability Sentiments
Brief 1 to 2 page abstract outlining each pitch
The “Edge” that we believe will catalyze the performance of the stock
Updates leading up to important company dates and events on our radar
What were some of the key approaches that led to SanaCurrents’ successful case studies?
Identifying the timing of binary events to determine when a stock will move.
Evaluating the track record of success in early trials of drug candidates.
Finding the management that is interested in advancing the a drug to approval – which often leads to a significant increase in stock value – instead of management that has been capitalized to fund exploratory research.
Determining the support of key opinion leaders for a specific drug or device.